Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression
An erratum to this article was published (J Clin Endocrinol Metab, 15 Mar 2024 ↗)
Authors' conclusion
INSL3 resembles testosterone as a sensitive marker of testicular suppression and reflects Leydig cell function, also during exposure to exogenous testosterone. Serum INSL3 measurements may complement testosterone as a Leydig cell marker in male reproductive disorders, during therapeutic testicular suppression as well as in surveillance of illicit use of androgens.
Study context
- Population
- Subjects before and after experimental or therapeutic testicular suppression: healthy young men, transgender girls (male sex assigned at birth) and patients with prostate cancer3 cohorts
- Participants
- 6 / 10 / 55
- Comparison
- Serum INSL3, testosterone and LH before vs after testicular suppression
- Healthy young menn = 6
- Transgender girlsn = 10
- Prostate cancern = 55
- Outcome
- Concomitant changes in serum INSL3, testosterone and LH during testicular suppression
Methodological details3 cohorts, before and after testicular suppression, INSL3 and testosterone by LC-MS/MS; LH by ultrasensitive immunoassay
- 3 cohorts
- Before and after testicular suppression
- INSL3 and testosterone by LC-MS/MS; LH by ultrasensitive immunoassay
Main finding
As reported in the abstract
Serum INSL3, testosterone and LH
- Healthy young men: INSL3, testosterone and LH decreased during Sustanon suppression and returned to baseline after release of suppression
- Transgender girls and prostate cancer: all 3 hormones decreased during therapeutic suppression
Original publication
Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression. J Clin Endocrinol Metab. Published 26 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →